Maximum Observed Plasma Concentration (Cmax) Day 3 (immediately post-dose, 0.75, and 2 hours post-dose) [clinicaltrials_resource:dd60443af10a19f7d170415fda0f6d82]
Cmax: tigecycline serum concentration measured in nanograms per milliliter (ng/mL) determined by a validated liquid chromatography with mass spectrophotometric (LC/MS/MS) detection method. Peak concentration was taken directly from the observed data.
clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]
Maximum Observed Plasma Concentration (Cmax) Day 3 (immediately post-dose, 0.75, and 2 hours post-dose) [clinicaltrials_resource:dd60443af10a19f7d170415fda0f6d82]
Cmax: tigecycline serum concentration measured in nanograms per milliliter (ng/mL) determined by a validated liquid chromatography with mass spectrophotometric (LC/MS/MS) detection method. Peak concentration was taken directly from the observed data.
Bio2RDF identifier
dd60443af10a19f7d170415fda0f6d82
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:dd60443af10a19f7d170415fda0f6d82
measure [clinicaltrials_vocabulary:measure]
Maximum Observed Plasma Concentration (Cmax)
time frame [clinicaltrials_vocabulary:time-frame]
Day 3 (immediately post-dose, 0.75, and 2 hours post-dose)
description
Cmax: tigecycline serum concen ...... rectly from the observed data.
identifier
clinicaltrials_resource:dd60443af10a19f7d170415fda0f6d82
title
Maximum Observed Plasma Concen ...... , 0.75, and 2 hours post-dose)
@en
type
label
Maximum Observed Plasma Concen ...... 0443af10a19f7d170415fda0f6d82]
@en